Abstract Body

Background: We here show the potential of a novel PKC activator, a hexanoate derivative of Ingenol (Ing-B) for purging the lentiviral reservoir in SIVmac251-infected macaques. cure. Here we present the preliminary results on a hexanoate derivative of Ingenol (Ing-B) in SIVmac251-infected macaques. Methodology: In a pilot trial in two SIVmac251-infected macaques, Ing-B was administered in escalating doses (1, 2.5, 5 mg BID) for one week each, alternated with off-treatment weeks. Blood samples were collected at 0, 3, and 7 days post-treatment for for analysis. In another experiment, two SIVmac251-infected macaques were treated with HAART composed by tenofovir, FTC, and raltegravir for 3 months to suppress viral load. After viral suppression, the animals were treated orally with Ing-B (0.2mg/kg BID) for 4 weeks and hematological , toxicological , immunological, and virological parameters were follow up weekly. Results: In dose escalation trial in non-suppressed animals, Ing-B activated blood leukocytes and transiently increased plasma VL (up to 1 Log) in SIVinfected macaques. Accordingly, plasma viral load and activation markers decreased during the washout periods. Ing-B was less toxic and can be orally administered to animals with no apparent side effects. Env sequencing showed an important turnover of different quasispecies sequences from tissue to plasma in different time points during Ing-B doses. In the second trial on monkeys with suppressed VLs, Ing-B could activate latent virus, resulting in several viral load spikes during 4 weeks on treatment in the presence of HAART. These viremic peaks were preceded by an elevation of CD69+ lymphocytes and monocytes. After removing HAART and Ing-B, the VLs decreased to undetectable levels (<50 copies) in both monkeys and VL control has been maintained for 5 weeks so far. The preliminary results of the ELISpot analysis were in line with the VL trends, displaying anti-Gag immune responses when viral loads became detectable. However, following therapy interruption, cell-mediated responses against Gag decreased and eventually disappeared paralleling the reduction of VL to undetectable levels. Additionally, the CD4+ lymphocytes isolated from the two animals after Ing-B treatment yielded no intracellular vRNA after induction with PMA and ionomycin for 18hs, suggesting its impact on the viral reservoir. Conclusions: Our data suggest that Ing-B is a viable candidate includable in drug combinations aimed at curing AIDS.